On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Advancing its DehydraTECH(TM) Technology, Having Demonstrated its Potential Across Multiple Areas of Application

  • Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
  • This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
  • The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
  • These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.

As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://ibn.fm/EVk0p). This devotion of a significant proportion of its resources reflects the company’s intent to establish areas of investigation for commercial pursuits while bringing it closer to tapping into vastly untapped markets with the potential for growth in the coming years.

The investments have paid off, with Lexaria having come a step closer to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/zZ96p). So far, previous clinical trials have shown DehydraTECH-processed CBD’s ability to lower blood pressure in patients over multiple weeks, a tremendous achievement for the company and for its technology.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/G9dm6).

This success has been replicated in other studies, most notably diabetes. In Lexaria’s pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels. With the American Diabetes Association (“ADA”) estimating the number of Americans with diabetes at 37.3 million as of 2019, there is a dire need for viable treatment options, and Lexaria is looking to address that (https://ibn.fm/A2R5W).

Lexaria’s DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market. Its NIC-H22-1 human nicotine study demonstrated a statistically significant difference between the time taken to achieve maximum blood saturation levels (“Tmax”) for DehydraTECH-nicotine at 2.3 and 3.1 minutes faster than alternatives currently in the market. In addition, DehydraTECH-nicotine represented a 15% and 20% faster response to achieve maximum blood saturation, a feat that few other players in the market have achieved.

“Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” noted Mr. Bunka.

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he added (https://ibn.fm/kxfsA).

Even with its achievements so far, Lexaria remains committed to pushing the envelope regarding the research and development of its DehydraTECH technology. So far, it has demonstrated its incredible potential across various areas of application as well as its viability in the market. The consistent push for further development reflects Lexaria’s understanding of its mission and commitment to creating shareholder value.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

From Our Blog

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

July 23, 2024

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have […]

Rotate your device 90° to view site.